The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
https://doi.org/10.21886/2219-8075-2018-9-4-22-27
Abstract
Objective: to characterize the efcacy of nelfnavir and lopinavir/ritonavir in the starting regimens of antiretroviral therapy for HIV-infected pediatric patients.
Materials and methods: 50 HIV-infected patients aged 24-36 months were treated with abacavir and lamivudine in combination with nelfnavir (24 children) or lopinavir/ritonavir (26 patients).
Results: Using both antiretroviral therapy schemes leads to suppression of HIV replication, improvement of clinical and immunological parameters. However, the treatment with lopinavir/ritonavir revealed a signifcant positive changes of HIV blood viral load, immune status and clinical picture. With the help of mathematical modeling, the signifcance of lopinavir/ritonavir appointment as an independent predictor of effectiveness prolongation of antiretroviral therapy has been proved. As a side effect of lopinavir/ritonavir developed dyspeptic symptoms.
Conclusion: Te results of the study indicate the high efcacy and safety of lopinavir/ritonavir use compared to nelfnavir in HIV-infected pediatric patients.
About the Authors
V. B. Denisenko,
Rostov State Medical University
Russian Federation
Russian Federation
Valentin B. Denisenko, Candidate of Medical Sciences,
Associate Professor of the Department of Childrens Infections,
Rostov-on-Don, Nakhichevansky 29, Phone: 8 (863)
232-73-58
E. N. Simovanyan
Rostov State Medical University
Russian Federation
Russian Federation
Emma N. Simovanyan, MD, Professor, Head of the
Department of Childrens Infections
344022, Rostov-on-Don, Nakhichevansky 29, Phone: 232-73-58
References
1. B-Lajoie MR, Drouin O, Bartlett G, Nguyen Q, Low A, Gavriilidis G еt al. Incidence and prevalence of opportunistic and other infections and the impact of antiretroviral therapy among HIV-infected children in low- and middle-income countries: a systematic review and meta-analysis. Clin. Infect. Dis. 2016; 62 (12): 1586-1594. doi: 10.1093/cid/ciw139.
2. HIV infection and AIDS: national leadership / ed. V.I. Pokrovsky. – Moscow: Geotar-Media; 2013 (In Russ).
3. Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old. Cocrane Database Syst. Rev. 2013; (10): CD010309. doi: 10.1002/14651858.CD010309.pub2.
4. Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L, Judd A et al. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. Int. J. Epidemiol. 2017; 46 (20): 453-465. doi: 10.1093/ije/dyw097.
5.
Review
For citations:
Denisenko, V.B., Simovanyan E.N. The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients. Medical Herald of the South of Russia. 2018;9(4):22-27. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-4-22-27
Views:
940
Email this article 